Beamr video compression achieves up to 50% improvement for AVs
Gravitas Capital LP, Executive Chairman at Tharimmune, Inc. (NASDAQ:THAR), has recently purchased 337,838 shares of common stock at a price of $1.48, according to a Form 4 filing with the Securities and Exchange Commission. The transaction, which occurred on June 20, 2025, amounted to $500,000. The purchase price represents a 13% premium to the current trading price of $1.31. According to InvestingPro data, the stock has declined 9% in the past week, with the company’s market capitalization now standing at $3.6 million.
Following the transaction, Gravitas Capital LP directly owns 732,424 shares of Tharimmune. InvestingPro analysis shows the company maintains a positive cash-to-debt position, though its overall financial health score is rated as weak. Subscribers can access 8 additional ProTips and comprehensive financial metrics for deeper insight into THAR’s performance.
In other recent news, Tharimmune, Inc. has announced several significant developments. The company released promising results from its Phase 1 study of TH104, a drug designed for opioid exposure prophylaxis, which showed a distinct metabolic profile and comparable safety to existing treatments. The FDA’s positive feedback suggests Tharimmune might submit a New Drug Application without further clinical trials. Additionally, Tharimmune has made notable executive changes, appointing Sireesh Appajosyula as CEO and Vincent LoPriore as Executive Chairman. These changes come alongside the departure of former CEO Randy Milby, who stepped down for personal reasons, with a settlement agreement in place. The company has also expanded its Board of Directors, adding Clay Kahler and Gary Stetz, as it prepares for upcoming strategic growth phases. These appointments reflect Tharimmune’s focus on enhancing its leadership and governance as it advances its clinical programs. Tharimmune continues to develop a diverse pipeline, including treatments for autoimmune diseases and a multispecific biologic platform targeting solid tumors.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.